BioLife Solutions, Inc. Stock

Equities

BLFS

US09062W2044

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 01:34:33 2024-04-19 pm EDT 5-day change 1st Jan Change
15.56 USD -1.92% Intraday chart for BioLife Solutions, Inc. -6.48% -5.05%
Sales 2024 * 111M Sales 2025 * 134M Capitalization 718M
Net income 2024 * -46M Net income 2025 * -23M EV / Sales 2024 * 6.45 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 5.36 x
P/E ratio 2024 *
-15.5 x
P/E ratio 2025 *
-31.1 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.44%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.76%
1 week-7.25%
Current month-14.50%
1 month-6.71%
3 months-6.87%
6 months+36.49%
Current year-2.40%
More quotes
1 week
14.84
Extreme 14.84
16.75
1 month
14.84
Extreme 14.84
19.18
Current year
14.50
Extreme 14.5
19.18
1 year
8.92
Extreme 8.9201
24.50
3 years
8.92
Extreme 8.9201
60.67
5 years
7.37
Extreme 7.37
60.67
10 years
1.43
Extreme 1.4328
60.67
More quotes
Managers TitleAgeSince
Founder 52 97-12-31
Chief Executive Officer 63 16-03-03
Director of Finance/CFO 39 14-12-31
Members of the board TitleAgeSince
Chief Executive Officer 63 16-03-03
Director/Board Member 62 13-11-17
Director/Board Member 62 22-08-31
More insiders
Date Price Change Volume
24-04-19 15.5 -2.30% 129 850
24-04-18 15.86 +4.76% 601,209
24-04-17 15.14 -5.37% 313,436
24-04-16 16 +2.04% 429,067
24-04-15 15.68 -4.97% 373,612

Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT

More quotes
BioLife Solutions, Inc. is a life sciences company. The Company develops, manufactures, and markets bioproduction tools and services which are designed to improve quality and de-risk biologic manufacturing, storage, distribution, and transportation in the cell and gene therapy (CGT) industry and broader biopharma markets. Its products are used in basic and applied research and commercial manufacturing of biologic-based therapies. Its bioproduction tools and services are comprised of three lines: Cell processing, Freezers and thaw systems and Biostorage services. Its proprietary biopreservation media products, HypoThermosol FRS and CryoStor Freeze Media, are formulated to mitigate preservation-induced, delayed-onset cell damage and death. Its ThawSTAR line includes thawing products that control the temperature and timing of the thawing process of biologic material. It operates five storage facilities in the United States and one facility in the Netherlands.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
15.86 USD
Average target price
23.12 USD
Spread / Average Target
+45.81%
Consensus